eFFECTOR Therapeutics, Inc. (EFTR)
NASDAQ: EFTR · IEX Real-Time Price · USD
+0.140 (7.87%)
Apr 23, 2024, 2:12 PM EDT - Market open

Company Description

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer.

The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.

The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E.

eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics logo
Country United States
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Dr. Stephen T. Worland Ph.D.

Contact Details

142 North Cedros Avenue, Suite B
Solana Beach, California 92075
United States
Phone (858) 925-8215
Website effector.com

Stock Details

Ticker Symbol EFTR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001828522
CUSIP Number 28202V108
ISIN Number US28202V2079
Employer ID 85-3306396
SIC Code 2834

Key Executives

Name Position
Dr. Stephen T. Worland Ph.D. Chief Executive Officer, President and Director
Michael Byrnes M.B.A. Chief Financial Officer
Dr. Douglas Warner M.D. Chief Medical Officer
Dr. Davide Ruggero Ph.D. Co-Founder and Member of Clinical and Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D. Co-Founder and Member of Clinical and Scientific Advisory Board

Latest SEC Filings

Date Type Title
Apr 16, 2024 PRE 14A Other preliminary proxy statements
Apr 4, 2024 424B3 Prospectus
Apr 4, 2024 8-K Current Report
Apr 4, 2024 424B5 Filing
Apr 2, 2024 EFFECT Notice of Effectiveness
Mar 29, 2024 POS AM Post-Effective amendments for registration statement
Mar 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 26, 2024 10-K Annual Report
Mar 25, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals